155 related articles for article (PubMed ID: 30137551)
1. First results on the DCVax phase III trial: raising more questions than providing answers.
Wick W; van den Bent MJ
Neuro Oncol; 2018 Sep; 20(10):1283-1284. PubMed ID: 30137551
[No Abstract] [Full Text] [Related]
2. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Liau LM; Ashkan K; Tran DD; Campian JL; Trusheim JE; Cobbs CS; Heth JA; Salacz M; Taylor S; D'Andre SD; Iwamoto FM; Dropcho EJ; Moshel YA; Walter KA; Pillainayagam CP; Aiken R; Chaudhary R; Goldlust SA; Bota DA; Duic P; Grewal J; Elinzano H; Toms SA; Lillehei KO; Mikkelsen T; Walbert T; Abram SR; Brenner AJ; Brem S; Ewend MG; Khagi S; Portnow J; Kim LJ; Loudon WG; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Lindhorst S; Lutzky J; Sloan AE; Schackert G; Krex D; Meisel HJ; Wu J; Davis RP; Duma C; Etame AB; Mathieu D; Kesari S; Piccioni D; Westphal M; Baskin DS; New PZ; Lacroix M; May SA; Pluard TJ; Tse V; Green RM; Villano JL; Pearlman M; Petrecca K; Schulder M; Taylor LP; Maida AE; Prins RM; Cloughesy TF; Mulholland P; Bosch ML
J Transl Med; 2018 May; 16(1):142. PubMed ID: 29843811
[TBL] [Abstract][Full Text] [Related]
3. DCVax®-L--developed by Northwest Biotherapeutics.
Polyzoidis S; Ashkan K
Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
[TBL] [Abstract][Full Text] [Related]
4. DCVax-Brain and DC vaccines in the treatment of GBM.
Wheeler CJ; Black KL
Expert Opin Investig Drugs; 2009 Apr; 18(4):509-19. PubMed ID: 19335279
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell immunotherapy for glioblastoma.
Polyzoidis S; Ashkan K
Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
[TBL] [Abstract][Full Text] [Related]
7. Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?
Van Gool S; De Vleeschouwer S
Expert Rev Neurother; 2012 Oct; 12(10):1173-6. PubMed ID: 23082731
[No Abstract] [Full Text] [Related]
8. Dendritic cell vaccines to combat glioblastoma.
Wheeler CJ
Expert Rev Neurother; 2010 Apr; 10(4):483-6. PubMed ID: 20367199
[No Abstract] [Full Text] [Related]
9. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.
Phuphanich S; Wheeler CJ; Rudnick JD; Mazer M; Wang H; Nuño MA; Richardson JE; Fan X; Ji J; Chu RM; Bender JG; Hawkins ES; Patil CG; Black KL; Yu JS
Cancer Immunol Immunother; 2013 Jan; 62(1):125-35. PubMed ID: 22847020
[TBL] [Abstract][Full Text] [Related]
10. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
Batich KA; Swartz AM; Sampson JH
Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
[TBL] [Abstract][Full Text] [Related]
11. Current vaccine trials in glioblastoma: a review.
Xu LW; Chow KK; Lim M; Li G
J Immunol Res; 2014; 2014():796856. PubMed ID: 24804271
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell immunotherapy for solid tumors: evaluation of the DCVax® platform in the treatment of glioblastoma multiforme.
Hdeib A; Sloan AE
CNS Oncol; 2015; 4(2):63-9. PubMed ID: 25768330
[TBL] [Abstract][Full Text] [Related]
13. [II. Autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma].
Maruyama T; Muragaki Y; Ishikawa E; Nitta M; Saito T; Ohno T; Iseki H; Okada Y
Gan To Kagaku Ryoho; 2015 Jun; 42(6):683-6. PubMed ID: 26242005
[No Abstract] [Full Text] [Related]
14. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
Hunn MK; Bauer E; Wood CE; Gasser O; Dzhelali M; Ancelet LR; Mester B; Sharples KJ; Findlay MP; Hamilton DA; Hermans IF
J Neurooncol; 2015 Jan; 121(2):319-29. PubMed ID: 25366363
[TBL] [Abstract][Full Text] [Related]
15. Technology evaluation: DCVax, Northwest Biotherapeutics.
Knutson KL
Curr Opin Mol Ther; 2002 Aug; 4(4):403-7. PubMed ID: 12222879
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: A meta-analysis of randomized controlled trials.
Lv L; Huang J; Xi H; Zhou X
Int Immunopharmacol; 2020 Jun; 83():106336. PubMed ID: 32213460
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of immunomodulation in human glioblastoma.
Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
[TBL] [Abstract][Full Text] [Related]
18. Current status of immunotherapy and gene therapy for high-grade gliomas.
Marsh JC; Goldfarb J; Shafman TD; Diaz AZ
Cancer Control; 2013 Jan; 20(1):43-8. PubMed ID: 23302906
[TBL] [Abstract][Full Text] [Related]
19. Agenus’ brain cancer vaccine doubles survival rate in GBM patients.
Riedmann EM
Hum Vaccin Immunother; 2014; 10(8):2139-40. PubMed ID: 25424916
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy trials for glioblastoma multiforme: promise and pitfalls.
Yong RL; Lonser RR
World Neurosurg; 2012; 77(5-6):636-8. PubMed ID: 22120230
[No Abstract] [Full Text] [Related]
[Next] [New Search]
